| BCRx | birth control drug |
|---|---|
| BDAC | Bureau of Drug Abuse Control |
| CADD | computer-aided drug design |
| CDER | Center for Drug Evaluation and Research; chronic granulomatous disease |
| CDP | chondrodysplasia punctata; chronic destructive periodontitis; collagenase-digestible protein; contin... |
| investigational new drug application | An application that must be submitted to a regulatory agency (the FDA in the united states) before a drug can be studied in humans. This application includes results of previous experiments; how, where, and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in animal studies; and how the compound is manufactured. (12 Dec 1998) |
|---|---|
| orphan drug | A pharmaceutical that has been abandoned or neglected during its development because it is seen as having only a limited potential for profit. Often a drug which only has a limited target population or which treats a rare disease, thus limiting its financial potential. (09 Oct 1997) |
| orphan drug act | Law giving incentives to companies developing a drug for a rare disease. The act gives the developer of the first drug of any one type a 7-year exclusive right to market the new drug. (14 Nov 1997) |
| orphan drug production | Production of drugs or biologicals which are unlikely to be manufactured by private industry unless special incentives are provided by others. (12 Dec 1998) |
| targeted drug delivery | Delivering a drug to a specific site in the body where it has the greatest effect, instead of allowing it to diffuse to various sites, where it may cause damage or trigger side effects. (14 Nov 1997) |
| united states food and drug administration | An agency of the public health service concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc. (12 Dec 1998) |
| fixed drug eruption | A type of drug eruption that recurs at a fixed site (or sites) following the administration of a particular drug; the lesions usually consist of intensely erythematous and purplish, sharply demarcated macules, and occasionally of herpetic vesicles; the affected areas undergo gradual involution, but flare and enlarge on readministration of the offending drug and may become hyperpigmented. Iodine eruption, an acneform or follicular eruption or granulomatous lesion caused by a reaction to systemic iodine or iodide administration. Kaposi's varicelliform eruption, a now rare complication of vaccinia superimposed on atopic dermatitis, with generalised vesicles and vesicopapules and high fever. Synonym: eczema vaccinatum. (05 Mar 2000) |
| food and drug administration | The U.S. Agency responsible for regulation of biotechnology foodproducts. The major laws under which the agency has regulatory powersinclude the Food, Drug, and Cosmetic act, and the Public Health Service Act. (09 Oct 1997) |
| food-drug interactions | The pharmacological result, either desirable or undesirable, of drugs interacting with components of the diet. (12 Dec 1998) |
| legislation, drug | Laws concerned with manufacturing, dispensing, and marketing of drugs. (12 Dec 1998) |